These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 11805217

  • 1. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells.
    Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R.
    J Pharmacol Exp Ther; 2002 Feb; 300(2):559-66. PubMed ID: 11805217
    [Abstract] [Full Text] [Related]

  • 2. Immunopharmacological potential of selective phosphodiesterase inhibition. II. Evidence for the involvement of an inhibitory-kappaB/nuclear factor-kappaB-sensitive pathway in alveolar epithelial cells.
    Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R.
    J Pharmacol Exp Ther; 2002 Feb; 300(2):567-76. PubMed ID: 11805218
    [Abstract] [Full Text] [Related]

  • 3. Amiloride blockades lipopolysaccharide-induced proinflammatory cytokine biosynthesis in an IkappaB-alpha/NF-kappaB-dependent mechanism. Evidence for the amplification of an antiinflammatory pathway in the alveolar epithelium.
    Haddad JJ, Land SC.
    Am J Respir Cell Mol Biol; 2002 Jan; 26(1):114-26. PubMed ID: 11751211
    [Abstract] [Full Text] [Related]

  • 4. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
    Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A.
    Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
    [Abstract] [Full Text] [Related]

  • 5. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM, Barnes PJ, Meja K, Giembycz MA.
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [Abstract] [Full Text] [Related]

  • 6. L-Buthionine-(S,R)-sulfoximine, an irreversible inhibitor of gamma-glutamylcysteine synthetase, augments LPS-mediated pro-inflammatory cytokine biosynthesis: evidence for the implication of an IkappaB-alpha/NF-kappaB insensitive pathway.
    Haddad JJ.
    Eur Cytokine Netw; 2001 Oct; 12(4):614-24. PubMed ID: 11781188
    [Abstract] [Full Text] [Related]

  • 7. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A, Ono K, Sato Y, Shioi T, Nose Y, Sasayama S.
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of glutathione-related enzymes augments LPS-mediated cytokine biosynthesis: involvement of an IkappaB/NF-kappaB-sensitive pathway in the alveolar epithelium.
    Haddad JJ, Safieh-Garabedian B, Saadé NE, Lauterbach R.
    Int Immunopharmacol; 2002 Oct; 2(11):1567-83. PubMed ID: 12433058
    [Abstract] [Full Text] [Related]

  • 9. Alpha-melanocyte-related tripeptide, Lys-d-Pro-Val, ameliorates endotoxin-induced nuclear factor kappaB translocation and activation: evidence for involvement of an interleukin-1beta193-195 receptor antagonism in the alveolar epithelium.
    Haddad JJ, Lauterbach R, Saadé NE, Safieh-Garabedian B, Land SC.
    Biochem J; 2001 Apr 01; 355(Pt 1):29-38. PubMed ID: 11256945
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM, Barnes PJ, Giembycz MA.
    Cell Biochem Biophys; 1998 Apr 01; 29(1-2):179-201. PubMed ID: 9631245
    [Abstract] [Full Text] [Related]

  • 11. Redox signaling-mediated regulation of lipopolysaccharide-induced proinflammatory cytokine biosynthesis in alveolar epithelial cells.
    Haddad JJ, Land SC.
    Antioxid Redox Signal; 2002 Feb 01; 4(1):179-93. PubMed ID: 11970852
    [Abstract] [Full Text] [Related]

  • 12. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.
    Kambayashi T, Jacob CO, Zhou D, Mazurek N, Fong M, Strassmann G.
    J Immunol; 1995 Nov 15; 155(10):4909-16. PubMed ID: 7594495
    [Abstract] [Full Text] [Related]

  • 13. Redox regulation of TNF-alpha biosynthesis: augmentation by irreversible inhibition of gamma-glutamylcysteine synthetase and the involvement of an IkappaB-alpha/NF-kappaB-independent pathway in alveolar epithelial cells.
    Haddad JJ, Saadé NE, Safieh-Garabedian B.
    Cell Signal; 2002 Mar 15; 14(3):211-8. PubMed ID: 11812649
    [Abstract] [Full Text] [Related]

  • 14. Glutathione depletion is associated with augmenting a proinflammatory signal: evidence for an antioxidant/pro-oxidant mechanism regulating cytokines in the alveolar epithelium.
    Haddad JJ.
    Cytokines Cell Mol Ther; 2000 Dec 15; 6(4):177-87. PubMed ID: 11565956
    [Abstract] [Full Text] [Related]

  • 15. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW, McConnell RT, Strickland AB, Gooding RC, Stimpson SA, Yarnall DP, Taylor JD, Furdon PJ.
    J Pharmacol Exp Ther; 1995 Mar 15; 272(3):1313-20. PubMed ID: 7891349
    [Abstract] [Full Text] [Related]

  • 16. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation.
    Sekut L, Yarnall D, Stimpson SA, Noel LS, Bateman-Fite R, Clark RL, Brackeen MF, Menius JA, Connolly KM.
    Clin Exp Immunol; 1995 Apr 15; 100(1):126-32. PubMed ID: 7697910
    [Abstract] [Full Text] [Related]

  • 17. Modulation of TNF and GM-CSF release from dispersed human nasal polyp cells and human whole blood by inhibitors of different PDE isoenzymes and glucocorticoids.
    Marx D, Tassabehji M, Heer S, Hüttenbrink KB, Szelenyi I.
    Pulm Pharmacol Ther; 2002 Apr 15; 15(1):7-15. PubMed ID: 11969359
    [Abstract] [Full Text] [Related]

  • 18. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
    Prabhakar U, Lipshutz D, Bartus JO, Slivjak MJ, Smith EF, Lee JC, Esser KM.
    Int J Immunopharmacol; 1994 Oct 15; 16(10):805-16. PubMed ID: 7843852
    [Abstract] [Full Text] [Related]

  • 19. Thymulin and zinc (Zn2+)-mediated inhibition of endotoxin-induced production of proinflammatory cytokines and NF-kappaB nuclear translocation and activation in the alveolar epithelium: unraveling the molecular immunomodulatory, anti-inflammatory effect of thymulin/Zn2+ in vitro.
    Haddad JJ.
    Mol Immunol; 2009 Dec 15; 47(2-3):205-14. PubMed ID: 19850345
    [Abstract] [Full Text] [Related]

  • 20. Redox/ROS regulation of lipopolysaccharide-induced mitogen-activated protein kinase (MAPK) activation and MAPK-mediated TNF-alpha biosynthesis.
    Haddad JJ, Land SC.
    Br J Pharmacol; 2002 Jan 15; 135(2):520-36. PubMed ID: 11815388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.